Return to homepagePandemic Pact

Intravacc - Broadly Protective Coronavirus Vaccine

  • Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
  • Total publications:0 publications
Grant search

Key facts

  • Disease

    COVID-19

  • start year

    2022

  • Known Financial Commitments (USD)

    $4,800,000

  • Funder

    Coalition for Epidemic Preparedness Innovations (CEPI)

  • Principal Investigator

    .

  • Research Location

    Netherlands

  • Lead Research Institution

    Intravacc

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Vaccine design and administration

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

October 6h, 2022; OSLO, Norway/Bilthoven, The Netherlands: CEPI, the Coalition for Epidemic Preparedness Innovations, and Dutch vaccine clinical development and manufacturing organization, Intravacc, today announced the latest funding award under CEPI's US$200m programme to advance the development of vaccines that provide broad protection against SARS-CoV-2 (including its variants) and other Betacoronaviruses. CEPI will provide seed funding of up to US$4.8 million to Intravacc'Äîa world leader in translational research and development of preventive and therapeutic vaccines'Äîto advance the development of a broadly protective Betacoronavirus vaccine candidate, which can be delivered intranasally. CEPI's funding will support preclinical development and testing of Intravacc's subunit vaccine candidate (Avacc 101), which is based on its Outer Membrane Vesicle (OMV) platform.